Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase 1/2 4Phase 3 2Phase 2/3 1

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

NIH 12INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × tanespimycin × Clear all
NCT00779428 2015-10-12

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Bristol-Myers Squibb

Phase 2 Completed
6 enrolled

Advanced Malignancies

NCT00969917 2015-04-14

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Withdrawn
Sarcoma

Liposarcoma

NCT01362400 2014-05-19

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
226 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT00564928 2012-12-11

IPI-504-04

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
19 enrolled
Genitourinary

Prostatic Neoplasms

NCT00817362 2012-12-11

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
29 enrolled
Breast

Breast Neoplasms

NCT00627419 2012-12-10

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
1 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡